Nitric Oxide-Releasing Liposomes for Treatment of <i>Mycobacterium abscessus</i> Infections

Nontuberculosis mycobacteria (NTM) are ubiquitous, opportunistic pathogens that cause severe respiratory infection, primarily in elderly and immunocompromised populations. The second most prevalent NTM pathogen, <i>Mycobacterium abscessus</i>, is considered the most refractory due to its fast growth rate, intracellular survivability, and antibiotic resistance. Treatments are thus sparse and generally ineffective, promoting antibiotic resistance upon chronic use. Nitric oxide (NO) is an endogenously produced free radical that exerts antimicrobial effects against pathogens via several mechanisms of action, and as such, it is unlikely to elicit resistance. Methyl tris diazeniumdiolate (MD3) is a small-molecule NO-releasing prodrug that is capable of sustained NO release, making it an attractive candidate as an antimicrobial therapeutic; however, its triple negative charge makes cellular uptake unlikely. As liposomes enable cellular uptake, their use as an MD3 delivery system may further enhance the utility of NO release for treating intracellular NTM infections. Herein, liposomal formulations were evaluated as a function of pH and buffer composition and optimized for MD3 loading to enable the delivery of bactericidal levels of NO. Planktonic studies with two clinically relevant morphotypes of <i>M. abscessus</i> revealed that lower p<i>K</i><sub>a</sub> liposomal systems employ a better antimicrobial efficacy. Prevention and eradication assays revealed that liposomal MD3 significantly improves biofilm inhibition compared to nonliposomal MD3 and was capable of eradicating biofilm bacteria at 4 mg mL<sup>-1</sup>. Liposomal MD3 and MD3 had similar reductions in intracellular bacterial load, achieving at least a three-log reduction at relevant concentrations. Fluorescence spectroscopy over 24 h demonstrated that liposomal encapsulation increased the intracellular concentration of a membrane-impermeable fluorophore by 3.4-fold. Confocal microscopy was used to visualize the increase in the number of cells containing intracellular NO and the sustained presence of NO within the cell, confirming that liposomal MD3 increases small-molecule internalization.

Authors

Institutions

Publication Details

Journal
ACS Applied Bio Materials
Published
2025-05-16
DOI
https://doi.org/10.1021/acsabm.5c00218
Citations
1
Primary Topic
Mycobacterium research and diagnosis
Type
article
Field-Weighted Citation Impact
1.35

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Nitric Oxide-Releasing Liposomes for Treatment of Mycobacterium abscessus Infections

Mark H. Schoenfisch, Sarah G. Nagy, Joseph J. Metiva
1 citations
ACS Applied Bio Materials
Mycobacterium research and diagnosis
1.35
article

Nitric Oxide-Releasing Liposomes for Treatment of Mycobacterium abscessus Infections

Mark H. Schoenfisch, Sarah G. Nagy, Joseph J. Metiva
article en
1 citations

Abstract

Nontuberculosis mycobacteria (NTM) are ubiquitous, opportunistic pathogens that cause severe respiratory infection, primarily in elderly and immunocompromised populations. The second most prevalent NTM pathogen, <i>Mycobacterium abscessus</i>, is considered the most refractory due to its fast growth rate, intracellular survivability, and antibiotic resistance. Treatments are thus sparse and generally ineffective, promoting antibiotic resistance upon chronic use. Nitric oxide (NO) is an endogenously produced free radical that exerts antimicrobial effects against pathogens via several mechanisms of action, and as such, it is unlikely to elicit resistance. Methyl tris diazeniumdiolate (MD3) is a small-molecule NO-releasing prodrug that is capable of sustained NO release, making it an attractive candidate as an antimicrobial therapeutic; however, its triple negative charge makes cellular uptake unlikely. As liposomes enable cellular uptake, their use as an MD3 delivery system may further enhance the utility of NO release for treating intracellular NTM infections. Herein, liposomal formulations were evaluated as a function of pH and buffer composition and optimized for MD3 loading to enable the delivery of bactericidal levels of NO. Planktonic studies with two clinically relevant morphotypes of <i>M. abscessus</i> revealed that lower p<i>K</i><sub>a</sub> liposomal systems employ a better antimicrobial efficacy. Prevention and eradication assays revealed that liposomal MD3 significantly improves biofilm inhibition compared to nonliposomal MD3 and was capable of eradicating biofilm bacteria at 4 mg mL<sup>-1</sup>. Liposomal MD3 and MD3 had similar reductions in intracellular bacterial load, achieving at least a three-log reduction at relevant concentrations. Fluorescence spectroscopy over 24 h demonstrated that liposomal encapsulation increased the intracellular concentration of a membrane-impermeable fluorophore by 3.4-fold. Confocal microscopy was used to visualize the increase in the number of cells containing intracellular NO and the sustained presence of NO within the cell, confirming that liposomal MD3 increases small-molecule internalization.

ACS Applied Bio MaterialsVol. 8(6)
University of North Carolina at Chapel Hill (US), Pharmac (NZ)
National Institutes of Health
Openalex Percentile: Top 20%
Mycobacterium research and diagnosis
1.35
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.